Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents.

Xu H, Kaye JA, Saltus CW, Crawford J, Gasal E, Goodnough LT.

Expert Rev Hematol. 2014 Oct;7(5):617-33. doi: 10.1586/17474086.2014.943730. Epub 2014 Aug 1. Review.

PMID:
25081548
2.

Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.

Arneson TJ, Li S, Gilbertson DT, Bridges KR, Acquavella JF, Collins AJ.

Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):857-64. doi: 10.1002/pds.3257. Epub 2012 Mar 26.

PMID:
22450901
3.

Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.

Hess G, Nordyke RJ, Hill J, Hulnick S.

Am J Hematol. 2010 Nov;85(11):838-43. doi: 10.1002/ajh.21837.

4.

A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.

Brophy GM, Sheehan V, Shapiro MJ, Lottenberg L, Scarlata D, Audhya P; ASSESS Study Group and Amgen Inc.

Clin Ther. 2008 Dec;30(12):2324-34. doi: 10.1016/j.clinthera.2008.12.024.

PMID:
19167591
5.

Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.

Spano JP, Khayat D.

Oncologist. 2008;13 Suppl 3:27-32. doi: 10.1634/theoncologist.13-S3-27. Review.

6.

Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?

Bormanis J, Quirt I, Chang J, Kouroukis CT, MacDonald D, Melosky B, Verma S, Couture F.

Crit Rev Oncol Hematol. 2013 Aug;87(2):132-9. doi: 10.1016/j.critrevonc.2012.12.010. Epub 2013 Jan 26. Review.

PMID:
23357249
7.
8.

Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.

Collins AJ, Monda KL, Molony JT, Li S, Gilbertson DT, Bradbury BD.

Am J Kidney Dis. 2014 Jun;63(6):997-1006. doi: 10.1053/j.ajkd.2013.10.052. Epub 2013 Dec 4.

PMID:
24315770
9.

Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.

Wong BC, Ravani P, Manns BJ, Lewin A, Zhang X, Chin R, Hemmelgarn BR, Tonelli M, Oliver MJ, Quinn RR.

Am J Kidney Dis. 2013 Nov;62(5):947-52. doi: 10.1053/j.ajkd.2013.05.017. Epub 2013 Jul 12.

PMID:
23856380
10.

Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.

Wetmore JB, Peng Y, Monda KL, Kats AM, Kim DH, Bradbury BD, Collins AJ, Gilbertson DT.

Am J Nephrol. 2015;41(4-5):354-61. doi: 10.1159/000431335. Epub 2015 Jun 17.

PMID:
26107376
11.

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Lung Cancer. 2012 Jun;76(3):478-85. doi: 10.1016/j.lungcan.2011.12.015. Epub 2012 Jan 25.

12.

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe.

Deger M, Eisterer W, Kutikova L, Salek S.

Support Care Cancer. 2013 Feb;21(2):485-93. doi: 10.1007/s00520-012-1538-0. Epub 2012 Jul 24. Review.

13.

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Support Care Cancer. 2012 Jan;20(1):159-65. doi: 10.1007/s00520-010-1083-7. Epub 2011 Feb 27.

14.

Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.

Tunceli O, Bailey RA, Stephenson JJ, Singer J.

J Oncol Pharm Pract. 2013 Dec;19(4):305-14. doi: 10.1177/1078155212466123. Epub 2012 Dec 12.

PMID:
23235918
15.

[Treatment of cancer chemotherapy-associated anemia in Japan - conditions and issues].

Yoshino I.

Gan To Kagaku Ryoho. 2014 Apr;41(4):426-31. Japanese.

PMID:
24743358
16.

Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.

Case AS, Rocconi RP, Kilgore LC, Barnes MN.

Gynecol Oncol. 2006 Jun;101(3):499-502. Epub 2006 Jan 10.

PMID:
16406064
17.

Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia--examination of practice in Germany.

Steinmetz T, Totzke U, Söling U, Groschek M, Mittermüller J, Schweigert M, Tesch H, Nawka S, Schmitz S, Tsamaloukas A.

Curr Med Res Opin. 2008 Oct;24(10):2751-6. doi: 10.1185/03007990802377057 . Epub 2008 Aug 19.

PMID:
18715527
18.

Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.

Nowrousian MR, Dunst J, Vaupel P.

Strahlenther Onkol. 2008 Mar;184(3):121-36. doi: 10.1007/s00066-008-1841-3. Review.

PMID:
18330508
19.

Erythropoiesis-stimulating agents in cancer patients: reflections on safety.

Wauters I, Vansteenkiste J.

Expert Rev Clin Pharmacol. 2011 Jul;4(4):467-76. doi: 10.1586/ecp.11.22. Review.

PMID:
22114856
20.

September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.

Aapro MS, Link H.

Oncologist. 2008;13 Suppl 3:33-6. doi: 10.1634/theoncologist.13-S3-33.

Supplemental Content

Support Center